novo nordisk glp-1 drugs Novo, Lilly buoyed by fast-growing drug sales Details of failed studies cast

Tirzepatide is a new drug targeting glucagon-like peptide 1(GLP1) and gastric inhibitory polypeptide (GIP) receptors

Alabamas attorney general recently filed a lawsuit against a medical spa alleging that it administered unapproved versions of GLP-1 weight loss drugs to patients without informing them that the formulations were not authorized by the FDA

Discover the benefits, mechanisms, and latest applications of GLP-1 receptor agonists in diabetes and obesity treatment.

Incorporating this botanical product into a balanced diet supports healthy metabolism as well as regular digestive and muscle function without risking undernutrition.*